The Claim
In patients with type 2 diabetes and early-stage chronic kidney disease, higher baseline serum concentrations of vitamin D-binding protein are associated with a reduced likelihood of achieving optimal 25(OH)D levels (>30 ng/mL) after three months of oral cholecalciferol supplementation.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In people with type 2 diabetes and early kidney disease, those with higher levels of vitamin D-binding protein in their blood at the start of treatment are less likely to reach healthy vitamin D levels after three months of taking vitamin D supplements.
See the scientific wording
In patients with type 2 diabetes and early-stage chronic kidney disease, higher serum levels of vitamin D-binding protein (VDBP) are associated with a reduced response to oral cholecalciferol supplementation, with patients achieving optimal 25(OH)D levels (>30 ng/mL) after three months having significantly lower baseline VDBP (mean 127.2 ng/mL) compared to those who did not (mean 274.7 ng/mL, p=0.036), suggesting VDBP concentration may limit vitamin D bioavailability and therapeutic efficacy.
When vitamin D-binding protein levels are high, it traps most of the vitamin D from supplements, leaving too little free vitamin D for the body to convert into its active form and use for essential functions.
What the research says
1 studyIn people with type 2 diabetes and mild kidney problems, those with more of a certain blood protein (VDBP) don’t respond as well to vitamin D pills because the protein traps the vitamin, leaving less for the body to use.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.